We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
-9.61%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$2.31B
AUM Growth
-$535M
Cap. Flow
-$185M
Cap. Flow %
-8.02%
Top 10 Hldgs %
64.82%
Holding
66
New
3
Increased
1
Reduced
14
Closed
7

Top Buys

Rank Stock Value
1
IMPL
Impel Pharmaceuticals Inc. Common Stock
IMPL
+$34.4M
2
VALN
Valneva
VALN
+$11M
3
ELEV
Elevation Oncology
ELEV
+$6.14M
4
MRUS
Merus
MRUS
+$5.9M

Top Sells

Rank Stock Value
1
LEGN icon
Legend Biotech
LEGN
+$61.1M
2
AMRS
Amyris Inc.
AMRS
+$22.7M
3
AKRO
Akero Therapeutics
AKRO
+$19.5M
4
ASND icon
Ascendis Pharma A/S
ASND
+$18.4M
5
EPIX
ESSA Pharma
EPIX
+$15M

Sector Composition

Rank Sector Weight
1 Healthcare 84.84%
2 Materials 8.25%
3 Financials 6.91%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVDL
26
DELISTED
Avadel Pharmaceuticals
AVDL
$19.8M 0.86%
2,937,093
– –
NVAX icon
27
Novavax
NVAX
$1.2B
$18.7M 0.81%
88,046
-69,441
-44% -$12.7M
GRCL
28
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$17.3M 0.75%
1,328,257
-194,737
-13% -$2.61M
NKTX icon
29
Nkarta
NKTX
$150M
$16.2M 0.7%
512,225
– –
EIGR
30
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$15.3M 0.66%
59,709
– –
CYTK icon
31
Cytokinetics
CYTK
$10.5B
$13.9M 0.6%
700,000
– –
MREO
32
Mereo BioPharma
MREO
$54.7M
$13.4M 0.58%
4,220,938
– –
CRIS icon
33
Curis
CRIS
$9.78M
$12.5M 0.54%
3,884
– –
KDNY
34
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$12.3M 0.53%
872,151
-334,115
-28% -$5.34M
DYN icon
35
Dyne Therapeutics
DYN
$4.7B
$12.2M 0.53%
577,642
– –
ARQT icon
36
Arcutis Biotherapeutics
ARQT
$3.36B
$11.8M 0.51%
433,585
-310,785
-42% -$8.75M
ARWR icon
37
Arrowhead Research
ARWR
$11.9B
$11.4M 0.49%
137,411
– –
KURA icon
38
Kura Oncology
KURA
$800M
$11M 0.47%
525,262
– –
DSGN icon
39
Design Therapeutics
DSGN
$761M
$10.6M 0.46%
530,991
– –
VALN
40
Valneva
VALN
$508M
$10.5M 0.46%
+400,000
New +$11M
ZYME icon
41
Zymeworks
ZYME
$1.61B
$9.92M 0.43%
286,064
– –
ASLN
42
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$9.38M 0.41%
71,023
– –
MRUS
43
DELISTED
Merus
MRUS
$9.31M 0.4%
442,000
+267,000
+153% +$5.9M
CDXS icon
44
Codexis
CDXS
$151M
$8.79M 0.38%
388,144
– –
STSA
45
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$8.69M 0.38%
1,232,394
– –
PASG icon
46
Passage Bio
PASG
$14.4M
$8.55M 0.37%
32,300
-38,375
-54% -$11.9M
LRMR icon
47
Larimar Therapeutics
LRMR
$397M
$7.85M 0.34%
799,662
– –
ELEV
48
DELISTED
Elevation Oncology
ELEV
$6.74M 0.29%
+496,843
New +$6.14M
AUPH icon
49
Aurinia Pharmaceuticals
AUPH
$1.91B
$6.49M 0.28%
500,732
– –
QTTB icon
50
Q32 Bio
QTTB
$466M
$6.2M 0.27%
47,397
– –
1
2
3

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
HCM
Hodges Capital Management Dallas, Texas $1.21B AUM 49% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM
CCM
Condor Capital Management Martinsville, New Jersey $1.2B AUM 13.18% 1-Year Est. Return

Vivo Capital's Q2 2021 Portfolio in Review

As of Q2 2021, Vivo Capital held 66 positions worth $2.31B, down 19% from $2.85B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Vivo Capital withdrew a net $185M in Q2 2021, closing 7 positions and reducing 14 holdings. Its most notable exit was Akero Therapeutics, an estimated $19.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 85% a quarter earlier, followed by Materials and Financials.

Against the trend, Vivo Capital opened a new position in Impel Pharmaceuticals Inc. Common Stock worth $25.5M.

  • Vivo Capital's largest Q2 2021 buy was Impel Pharmaceuticals Inc. Common Stock: 2,884,789 shares worth $25.5M.
  • Vivo Capital added most to Merus in Q2 2021, an estimated $5.9M increase.
  • Vivo Capital's biggest Q2 2021 reduction was Legend Biotech, cutting an estimated $61.1M.
  • Vivo Capital fully exited Akero Therapeutics in Q2 2021, selling an estimated $19.5M.
  • Vivo Capital's ten largest holdings make up 65% of its $2.31B portfolio in Q2 2021.
  • Vivo Capital opened 3 new positions and closed 7 in Q2 2021.
  • Vivo Capital's portfolio value fell 19% quarter-over-quarter to $2.31B.

Based on Vivo Capital's 13F filing for Q2 2021, filed 16 Aug 2021.